Tagged with Ophthalmology

China With nearly half of Chinese adults now suffering from myopia and age-related eye conditions on the rise, China is on the brink of an ophthalmology boom — a market set to more than double by 2031. While global players like Santen have taken an early lead, a new wave of…

China Ye Liu, CEO and cofounder of OcuMension Therapeutics, speaks about the challenges and triumphs of running one of China’s most ambitious ophthalmology-focused biopharmaceutical companies. Launched with USD 5 million and no initial products, OcuMension now leads in China’s ophthalmology drug development, maintains rapid growth, and is preparing for global reach.…

Saudi Arabia Mohamed Ayad, representing Santen as the Head of the Middle East, discusses the Japanese multinational firm’s growing presence and strategic focus in the region. He shares insights into the challenges and opportunities within the eye health care and ophthalmology market, Santen’s innovative approach to product offerings, and the company’s commitment…

Saudi Arabia Ali ElAkkad, General Manager of Bausch & Lomb Pharma and Consumer for the Middle East and Pakistan, shares insights into the company’s strategic priorities and its commitment to innovation in the region. He discusses how Bausch & Lomb is focusing on bringing high-quality ophthalmology products to market, fostering a high-performance…

Saudi Arabia Alcon’s Fadi AlSafadi shares his insights on the evolving eye care landscape in the dynamic Middle East and Africa region. He discusses Alcon’s innovative initiatives, including advancements in digitalisation, sustainability efforts, and their approach to enhancing accessibility and education. AlSafadi also highlights Alcon’s commitment to improving healthcare outcomes, fostering local…

Japan Santen is on a mission to reshape the future of eye health. With three major product launches ahead, bold biotech deals, and a revamped global strategy, the Japanese pharma is doubling down on its ophthalmology dominance. Fresh off a transformational reorganization and a landmark myopia approval, Santen is proving that…

China Eye health, despite being essential for most of us in our daily lives, receives significantly less research funding than fields like cancer or diabetes. According to IQVIA, global spending on oncology is expected to reach USD 440 billion by 2028, while ophthalmology will see just USD 38 billion. However, conditions…

China Shawn Xiang, corporate officer and China head at Santen, discusses the eye care specialist’s second-largest market and the challenges of diagnosing and managing eye conditions in China where a lack of public awareness is coupled with the country’s shortage of clinical capacity in ophthalmology. He remarks on Santen’s “China 2.0”…

Switzerland Marianthi Psaha, President, Head of EMEA for Santen, discusses the company’s journey towards becoming a specialized leader in ophthalmology—highlighting how digital transformation, innovation in myopia treatment, and strategic partnerships are reshaping its impact on eye health across Europe. Psaha delves into the challenges of building awareness of the area’s importance…

China Established in 2017 as a spin-off from Lee’s Pharmaceutical, Zhaoke Ophthalmology is aiming to be a global player in the ophthalmology field, building on its strong footprint in China and Asia to eventually establish operations in the US and Europe. President and Chief Scientific Officer Lau Lit Fui outlines how…

Belgium Théa veteran and GM of the French ophthalmology midcap’s BeLux affiliate, Ivan Perrichon, reveals the company’s plans to pursue its growth trajectory, launch ten new products in Belgium and reach a local turnover of EUR 30 million over the next five years. He also discusses Théa’s plans to address progressive…

Italy Historically, SIFI has been a modest local player focused on ophthalmic products, but in recent years the company has set some ambitious goals for itself—becoming a leading force in European ophthalmic markets, breaking into orphan drugs and adding value in the glaucoma field—and is now seeing its ambitions become a…